Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

NCT ID: NCT01083758

Last Updated: 2025-03-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-04-30
• Study Completion Date: 2012-10-31

Brief Summary

The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 topical suspension in adolescent subjects (aged 12 to 17 years) with scalp psoriasis. LEO 80185 topical suspension has marketing approval in many countries under the brand names Taclonex Scalp® Topical Suspension and Xamiol® gel for the treatment of scalp psoriasis in adults. No studies have been performed in subjects younger than 18 years.

Conditions

Scalp Psoriasis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

LEO 80185 (Taclonex® Scalp topical suspension/ Xamiol® gel)

Group Type: OTHER

LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)

Intervention Type: DRUG

Topical suspension applied once daily for up to 8 weeks

Interventions

LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)

Topical suspension applied once daily for up to 8 weeks

Intervention Type: DRUG

Other Intervention Names

LEO 80185 topical suspension

Eligibility Criteria

Inclusion Criteria

• Signed informed consent given by parent(s) or legal guardian following their receipt of verbal and written information about the study
• Subjects will receive verbal and written information and will provide written assent to the study
• Any race or ethnicity
• Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs
• At Screening Visit 2 and Visit 1 a clinical diagnosis of scalp psoriasis which is:

• amenable to topical treatment with a maximum of 60 g of study medication per week, and
• of an extent of more than or equal to 20% of the scalp area
• of at least moderate severity according to the investigator's global assessment
• Subjects with a normal HPA axis function at SV2 including serum cortisol concentration above 5 mcg/dl before ACTH challenge and serum cortisol concentration above 18 mcg/dl 30 minutes after ACTH challenge
• A serum albumin-corrected calcium below the upper reference limit at Screening Visit 2
• Females of child-bearing potential must have a negative urine pregnancy test result and must agree to use a highly effective method of contraception (abstinence is an acceptable method).

Exclusion Criteria

• A history of serious allergy, allergic asthma or serious allergic skin rash
• Known or suspected hypersensitivity to any medication (including ACTH/cosyntropin/tetracosactide) or to any component of the LEO 80185 topical suspension or CORTROSYN
• Systemic treatment with corticosteroids (including inhaled and nasal steroids) within 12 weeks prior to Screening Visit 2 or during the study
• Topical treatment with corticosteroids within 2 weeks prior to Screening Visit 2 or during the study
• Oestrogen therapy (including contraceptives) or any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to Screening Visit 2 or during the study
• Enzymatic inductors (e.g., barbiturates, phenytoin, rifampicin)or cytochrome P450 inhibitors (e.g., ketoconazole, itraconazole, metronidazole) within 4 weeks prior to Screening Visit 2 or during the study. Topical ketoconazole 2 weeks prior to Screening Visit 2
• Hypoglycemic sulfonamides or Antidepressive medications within 4 weeks prior to Screening Visit 2 or during the study
• Known or suspected endocrine disorder that may affect the results of the ACTH challenge test
• Systemic treatment with biological therapies (marketed or not marketed), with a possible effect on scalp psoriasis within the following time period prior to Visit 1 and during the study within 4 weeks/5 half-lives (whichever is longer) prior to Visit 1
• Systemic treatment with therapies other than biologicals, with a possible effect on scalp psoriasis (e.g., retinoids, immunosuppressants, PUVA) within 4 weeks prior to Visit 1 (Day 0) or during the study
• Planned initiation of, or changes to, concomitant medication that could affect scalp psoriasis (e.g., betablockers, chloroquine, lithium, ACE inhibitors) during the study
• Other inflammatory skin diseases that may confound the evaluation of scalp psoriasis
• Known or suspected disorders of calcium metabolism associated with hypercalcaemia

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LEO Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lawrence F Eichenfield, MD

Role: PRINCIPAL_INVESTIGATOR

Rady Children's Hospital, San Diego

Locations

Rady Children's Hospital San Diego

San Diego, California, United States

Leavitt Medical Associates of Florida, Inc.

Jacksonville, Florida, United States

Leavitt Medical Associates of Florida, Inc.

Ormond Beach, Florida, United States

Peachtree Dermatology Associates, PC

Atlanta, Georgia, United States

Deaconess Clinic

Evansville, Indiana, United States

Skin Specialists, PC

Omaha, Nebraska, United States

Countries

United States

Related Links

https://www.leopharmatrials.com/en

Clinical Trials at LEO Pharma

Other Identifiers

2008-007606-11

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MBL 0801

Identifier Type: -

Identifier Source: org_study_id